We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,775.00 | 1,774.50 | 1,775.50 | 1,778.50 | 1,769.00 | 1,775.50 | 2,851,224 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.82 | 73.06B |
From May 2021 to May 2024
By Sabela Ojea
GlaxoSmithKline PLC said Wednesday that its Nucala monoclonal antibody has been approved in Europe by the European Commission for three additional eosinophil-driven diseases.
The British pharma major said this antibody is the first approved targeted treatment for use in four of these eosinophil-driven conditions.
Eosinophil-driven diseases are inflammatory conditions linked to elevated levels of eosinophils, a type of white blood cell, the company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 17, 2021 02:40 ET (07:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
